Posted inAutoimmune Diseases, Clinical Trials, Neuroscience Ublyxi: Highly Effective Drug for Multiple Sclerosis May 31, 2022September 8, 2022 Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
